[go: up one dir, main page]

EA201791691A1 - ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d - Google Patents

ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d

Info

Publication number
EA201791691A1
EA201791691A1 EA201791691A EA201791691A EA201791691A1 EA 201791691 A1 EA201791691 A1 EA 201791691A1 EA 201791691 A EA201791691 A EA 201791691A EA 201791691 A EA201791691 A EA 201791691A EA 201791691 A1 EA201791691 A1 EA 201791691A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cd1d
domain antibodies
compounds
specifically
antibodies directed
Prior art date
Application number
EA201791691A
Other languages
English (en)
Inventor
Дер Влит Йоханнес Йелле Ван
Грюейль Таня Дениз Де
Хендрик Маринус Виллем Верхель
Брейн Рене Корнелиа Герарда Де
Роланд Ламерис
Original Assignee
Лава Терапьютикс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лава Терапьютикс Б.В. filed Critical Лава Терапьютикс Б.В.
Publication of EA201791691A1 publication Critical patent/EA201791691A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к соединениям, конкретно - к полипептидам, которые специфично связываются с неклассическим MHC-белком CDHd и модулируют CD1d-опосредованные биологические функции. Конкретно, изобретение относится к таким соединениям и полипептидам, содержащим или состоящим по меньшей мере из одного однодоменного антитела, и где по меньшей мере одно однодоменное антитело специфично связывается с CD1d. Также предлагаются способы и применение с использованием таких соединений, полипептидов и/или однодоменных антител.
EA201791691A 2015-01-27 2016-01-27 ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d EA201791691A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2014192 2015-01-27
PCT/NL2016/050064 WO2016122320A1 (en) 2015-01-27 2016-01-27 Single domain antibodies targeting cd1d

Publications (1)

Publication Number Publication Date
EA201791691A1 true EA201791691A1 (ru) 2018-01-31

Family

ID=52630466

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791691A EA201791691A1 (ru) 2015-01-27 2016-01-27 ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d

Country Status (11)

Country Link
US (4) US10501541B2 (ru)
EP (1) EP3250608B1 (ru)
JP (2) JP6743051B2 (ru)
KR (2) KR102574729B1 (ru)
CN (2) CN107531787B (ru)
AU (2) AU2016212777B2 (ru)
CA (1) CA2975078A1 (ru)
EA (1) EA201791691A1 (ru)
MX (1) MX386714B (ru)
SG (1) SG11201706128PA (ru)
WO (1) WO2016122320A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975078A1 (en) 2015-01-27 2016-08-04 Lava Therapeutics B.V. Single domain antibodies targeting cd1d
AU2019344300A1 (en) * 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
AU2019390483A1 (en) * 2018-11-30 2021-07-15 Aleta Biotherapeutics Inc. Single domain antibodies against CLL-1
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
CN114195891B (zh) * 2021-12-22 2023-05-12 北京世纪沃德生物科技有限公司 一种crp驼源单域抗体及其制备方法和应用
EP4285926A1 (en) * 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
WO2024256586A1 (en) 2023-06-14 2024-12-19 LAVA Therapeutics N.V. Cd1d antibodies and methods of use

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
DK0751780T3 (da) 1993-06-21 2003-10-13 Brigham & Womens Hospital Fremgangsmåder til isolering af CD1-fremviste antigener, vacciner, som omfatter CD1-fremviste antigener, og cellelinier til anvendelse i nævnte fremgangsmåder
WO2000046383A2 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
WO2001009300A2 (en) 1999-08-02 2001-02-08 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
EP1229790A4 (en) 1999-09-30 2004-06-16 Nat Jewish Med & Res Center MODULATION OF -G (G) -G (D) T CELLS FOR REGULATING THE RESPIRATORY HYPERSENSITIVITY
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
AU2001259230A1 (en) 2000-04-28 2001-11-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions
PT1297017E (pt) 2000-06-19 2012-09-04 Gen Hospital Corp Composições e métodos de anticorpos monoclonais e policlonais específicos para subpopulações de célula t
US7419958B2 (en) 2001-03-26 2008-09-02 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
AU2003208415B2 (en) 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
CA2492671C (en) 2002-03-22 2012-04-17 Aprogen, Inc. Humanized antibody and process for preparing same
AU2003234443A1 (en) 2002-05-01 2003-11-17 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
EP1565482B1 (en) 2002-10-23 2014-04-30 Ludwig Institute for Cancer Research Ltd. A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2004062551A2 (en) 2003-01-10 2004-07-29 Ablynx N.V. RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
WO2005046711A2 (en) 2003-11-07 2005-05-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing
EA010350B1 (ru) 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
AU2005274649B2 (en) 2004-08-19 2010-09-09 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma delta T cells and use in immunotherapy
CN101031307B (zh) 2004-11-02 2012-09-05 小利兰斯坦福大学托管委员会 抑制nkt细胞的制药用途
US8338173B2 (en) 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
LT1990410T (lt) * 2006-02-22 2020-03-10 Riken Imunoterapija, panaudojant ląstelę, gebančią koekspresuoti tikslinį antigeną ir cd1d, ir kuri buvo aktyvinta cd1d ligandu
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
EP1878440A1 (en) 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
US8012484B2 (en) 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
EP2058388A1 (en) * 2007-10-05 2009-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-conventional NKT cells for use in cancer therapy
WO2010130830A2 (en) * 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
EA201400447A1 (ru) * 2011-10-14 2014-09-30 Тева Фармасьютикал Австралия Пти Лтд. АНТИТЕЛА К CD1d
AU2013201422B2 (en) 2012-01-23 2015-04-09 Ablynx Nv Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors
US9891211B2 (en) 2012-03-28 2018-02-13 Gadeta B.V. Gamma 9 delta 2 T cell receptors
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3049090A1 (en) 2013-06-28 2016-08-03 The Scripps Research Institute Nkt cell ligands and methods of use
US10106623B2 (en) 2014-02-12 2018-10-23 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
EP3129404B1 (en) 2014-04-10 2026-01-28 LAVA Therapeutics N.V. Immunoglobulins binding human vgamma9vdelta2 t cell receptors
CN106459954A (zh) 2014-05-13 2017-02-22 中外制药株式会社 用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
EP3164713A1 (en) 2014-07-02 2017-05-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for diagnosing and treating cd1d restricted gamma/delta t cell lymphomas
DK3220926T3 (da) 2014-11-17 2025-03-24 Adicet Therapeutics Inc Konstruerede gamma-delta-t-celler
CA2975078A1 (en) 2015-01-27 2016-08-04 Lava Therapeutics B.V. Single domain antibodies targeting cd1d
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
CN104829730A (zh) 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3450460B1 (en) 2016-04-29 2023-07-12 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
US20180028566A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
TWI687227B (zh) 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
AU2019247229A1 (en) 2018-04-05 2020-10-15 Novartis Ag Trispecific binding molecules against cancers and uses thereof
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
CA3131014A1 (en) 2019-02-21 2020-08-27 Andreas Loew Anti-tcr antibody molecules and uses thereof
KR20220017892A (ko) 2019-05-08 2022-02-14 얀센 바이오테크 인코포레이티드 T세포 매개 면역의 조절을 위한 물질 및 방법
US20220403025A1 (en) 2019-08-16 2022-12-22 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies
KR20220045980A (ko) 2019-08-16 2022-04-13 감마델타 테라퓨틱스 리미티드 체외 감마 델타 t 세포 집단
CA3173268A1 (en) 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
EP4118121A4 (en) 2020-03-13 2024-05-15 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MODULATING T CELL-MEDIATED IMMUNITY
EP4237003A4 (en) 2020-10-28 2025-07-09 Janssen Biotech Inc COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY

Also Published As

Publication number Publication date
US11591394B2 (en) 2023-02-28
US20200115450A1 (en) 2020-04-16
MX386714B (es) 2025-03-11
US20180142020A1 (en) 2018-05-24
EP3250608A1 (en) 2017-12-06
AU2016212777A1 (en) 2017-08-17
HK1247937A1 (en) 2018-10-05
MX2017009680A (es) 2018-04-13
US12110328B2 (en) 2024-10-08
JP6743051B2 (ja) 2020-08-19
KR102574729B1 (ko) 2023-09-04
WO2016122320A1 (en) 2016-08-04
CA2975078A1 (en) 2016-08-04
US20240425592A1 (en) 2024-12-26
SG11201706128PA (en) 2017-08-30
JP2018508229A (ja) 2018-03-29
AU2022200922A1 (en) 2022-03-03
CN114504645A (zh) 2022-05-17
AU2016212777B2 (en) 2021-11-18
CN107531787A (zh) 2018-01-02
EP3250608B1 (en) 2024-08-21
US10501541B2 (en) 2019-12-10
JP7165701B2 (ja) 2022-11-04
US20240067726A1 (en) 2024-02-29
KR20170128254A (ko) 2017-11-22
CN107531787B (zh) 2022-01-18
JP2020172550A (ja) 2020-10-22
KR20230132604A (ko) 2023-09-15

Similar Documents

Publication Publication Date Title
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA201891992A1 (ru) Химерные рецепторы и способы их применения
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
IL281787A (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA201891040A1 (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
ZA201708265B (en) Tigit-binding agents and uses thereof
EA201792193A1 (ru) Конструкции биспецифического антитела для cdh3 и cd3
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
CR20180225A (es) Anticuerpo anti-tigit y métodos de uso
EA201892440A1 (ru) Антитела к tl1a и их применения
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
PT3176181T (pt) Anticorpo monoclonal anti-ctla4 ou fragmento de ligação ao antigénio do mesmo, composição medicinal e utilização
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
MX395074B (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos